Korean J Ophthalmol.  2006 Jun;20(2):82-86. 10.3341/kjo.2006.20.2.82.

Thyroid Associated Orbitopathy following Periocular Surgery

• Kim SJ
• Kim BJ
• Lee HB
• Tsirbas A
• Kazim M

• KMID: 1099040
• DOI: http://doi.org/10.3341/kjo.2006.20.2.82

Abstract

PURPOSE: To descirbe a series of patients in which Thyroid Associated Orbitopathy (TAO) occurred after periocular surgery. METHODS: A retrospective case review of patients who developed TAO in close temporal association with periocular surgical interventions and presented at the orbital clinic from 1997 to 2004. History of previous thyroid abnormality and the lack of TAO signs and symptoms before surgery were reviewed and analyzed. RESULTS: Nine patients that developed TAO in association with periocular surgery were identified. All were women with an average age of 59.3years. (range: 45-75 years). The patients divided into two groups. Group 1 consisted of four patients who had previously been diagnosed with Graves' hyperthyroidism (GH). They ranged in age from 48 to 75 years (average: 58.8 years). The diagnosis of GH had been made an average of 50.5 months (range: 12-96 months) before presentation with TAO. Group 2 consisted of five patients who had no previous history of thyroid abnormality. They ranged in age from 45 to 74 years (average: 60.2 years). No patients had any signs or symptoms of TAO before their recent presentation. CONCLUSIONS: Periocular surgery may lead to local inflammatory events that may contribute to the instigation of TAO in predisposed individuals.

Keyword

Periocular surgery; Thyroid associated orbitopathy

MeSH Terms

Risk Factors
Retrospective Studies
Postoperative Complications
Ophthalmologic Surgical Procedures/*adverse effects
Middle Aged
Humans
Graves Ophthalmopathy/*etiology
Follow-Up Studies
Female
Aged

Reference

1. Graves RJ. Graves disease. London Med Surg J. 1835. 7:516.

2. Von Basedow C. Exophthalmos durch hyperetrophie des Zellgewebes in der augenhohle. Wehnscher ges Heil. 1840. 6:197–204. 220–228.

3. Rootman J. Diseases of the Orbit; A multidisciplinary Approach. 2003. v. 1:2nd.Ed. Philadelpia: Lippincott Williams & Wilkins;chap. 8.

4. Sergott RC, Glaser JS. Graves ophthalmopathy. A clinical and immunologic review. Surv Ophthalmol. 1981. 26:1–21.

5. Glaser JS. Graves' ophthalmopathy. Arch Ophthalmol. 1984. 102:1448–1449.

6. Felberg NT, Sergott RC, Savino PJ, et al. Lymphocyte subpopulations in Graves Ophthalmopathy. Arch Ophthalmol. 1985. 103:656–659.

7. Solomon DH, Green DE, Snuder NJ, et al. Clinical significance of the long acting thyroid stimulator of Graves disease. Clin Res. 1964. 12:119.

8. Theofilopoulos AN, Dixon FJ. Autoimmune disease: Immunopathology and etipathogenesis. Am J Pathol. 1982. 108:319–365.

9. Bartley GB, Fatourechi V, Kadrmas EF, et al. Long term follow-up of Graves ophthalmopathy in an incidence cohort. Ophthalmology. 1996. 103:958–962.

10. Rundle FF, Wilson CW. Development and course of exophthalmos and ophthalmoplegia in graves disease with special reference to the effect of thyroidectomy. Clin Sc. 1944. 5:177–194.

11. Kendler DL, Lippa J, Rootman J. The initial clinical characteristics of graves orbitopathy vary with age and age. Arch Ophthalmol. 1993. 111:197–201.

12. Busuttil IS, Frauman AG. Extrathyroidal manifestations of Graves disease. The thyrotropin receptor is expressed in extraocular, but not cardiac muscle tissues. J Clin Endocrinol Metab. 2001. 86:2315–2319.

13. Gunji K, Kubota S, Swanson J, et al. Role of the eye muscles in thyroid eye disease: identification of the principal autoantigens. Thyroid. 1998. 8:553–556.

14. Ludgate M, Crisp M, Lane C, et al. The thyrotropin receptor in thyroid eye disease. Thyroid. 1998. 8:411–413.

15. Dutton CM, Joba W, Spitzweg C, et al. Thyrotropin receptor expression in adrenal,kidney and thymus. Thyroid. 1997. 7:879–884.

16. Smith TJ, Koumas L, Gagnon A, et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid associated orbitopathy. J Clin Endocrinol Metab. 2002. 87:385–392.

17. Jakobiec FA. Ocular anatomy, embryology and teratology. Harper and row. 1982. Philadelphia: 12–13. 97–119.

18. Cao HJ, Wang HS, Zhang Y, et al. Activation of human orbital fibroblasts through CD40 engagements results in a dynamic induction of hyaluron synthesis and prostaglandin endoperoxide h synthase-2 expression:insights into potential pathogenic mechanisms of thyroid associated ophthalmopathy. J Biol Chem. 1998. 273:29615–29625.

19. Sempowski GD, Rozenblit J, Smith TJ, Phipps RP. Human orbital fibroblasts are activated through CD40 to induce pro-inflammatory cytokine production. Am J Physiol. 1998. 274:C707–C714.

20. Sorisky AS, Pardasani D, Gagnon A, Smith TJ. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab. 1996. 81:3428–3431.

21. Smith TJ, Sempowski GD, Wang HS, et al. Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts. J Clin Endocrinol Metab. 1995. 80:2620–2625.

22. Smith TJ. Orbital fibroblasts exhibit novel pattern of responses to proinflammatory cytokines; potential basis for the pathogenesis of thyroid associated orbitopathy. Thyroid. 2002. 12:197–203.

23. Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans and diseases of the Thyroid. Endocrine Rev. 1989. 10:366–391.

24. Feldon SE, Muramatsu S, Weiner JM. Clinical classification of Graves ophthalmopathy: identification of risk factors for optic neuropathy. Arch Ophthalmol. 1984. 102:1469–1472.

25. Rapoport B, Alsabeh R, Aftergood D, McLachlan SM. Elephantiasic pretibial myxedema: insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves disease. Thyroid. 2000. 10:629–630.

26. Hamed LM, Lingua RW. Thyroid eye disease presenting after cataract surgery. J Paediatr ophthalmol Strabismus. 1990. 27:10–15.

27. Wai DC, Ho S, Seah L, et al. Severe Graves ophthalmopathy after retrobulbar anaesthesia for cataract extraction in a patient with mild stable Thyroid eye Disease. Thyroid. 2003. 13:823–826.

28. Bartalena L, Marcocci C, Bogazzi F, et al. Relationship between therapy for hyperthyroidism and the course of Graves Ophthalmopathy. N Engl J Med. 1998. 338:73–78.